Astel­las los­es patent in­fringe­ment case over block­buster blad­der drug

Astel­las just faced a set­back in fed­er­al court — with a judge in­val­i­dat­ing three claims on a patent sur­round­ing an ex­tend­ed re­lease ver­sion of its block­buster over­ac­tive blad­der drug.

The four-page rul­ing was hand­ed down Fri­day in the US Dis­trict Court in the Dis­trict of Delaware. The case cen­ters around Astel­las’ Myr­be­triq (mirabegron), which made over $1.3 bil­lion in sales last year and was ap­proved by the FDA in 2012.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER